Drugs / UB-312
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05634876 | May 2023 → Feb 2025 | Parkinson disease, multiple system atrophy | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT04075318 | Aug 2019 → Mar 2023 | Parkinson disease | United Neuroscience Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04075318 ↗ |
| Modality | Vaccine | “UB-312 is a UBITh®-enhanced synthetic peptide-based vaccine” NCT04075318 ↗ |
| Route | Intramuscular | “UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13” NCT04075318 ↗ |